Q2 FY2026 EarningsQ2 FY26 results beat consensus on the top and bottom lines: revenue was $6.3M vs. $5.3M expected, and GAAP EPS was -$0.52 vs. -$0.53 expected. Collaboration revenue, while down 38% YoY, exceeded estimates due to milestones in the Amgen and Novartis programs. The net loss of $67.3M was slightly narrower than the $67.9M consensus, supported by a healthy cash position of $457.4M which extends the runway into H1 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Generate Biomedicines(GENB) the Revenue is 6.314 M (--%), Beat estimate;the EBIT is -71.61 M (--%), Miss estimate;the EPS is -0.52 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B--
0.01B--
+0.00B--%
EBITMiss expectations
-0.07B--
-0.07B--
-0.00B--%
EPSExceed expectations
-0.52--
-0.53--
+0.0100--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf